Harbour BioMed is a global biotechnology company discovering and developing innovative therapeutics for cancer with a focus on immuno-oncology. The company's discovery and development programs are centered around its two patented transgenic mouse platforms for human antibody discovery. The company is building its proprietary pipeline internally, through collaborations with co-development partners, and selective preclinical and clinical stage asset acquisitions. Harbour BioMed also licenses the platforms to companies and academic institutions through its Harbour Antibodies subsidiary.